Výsledky vyhledávání - "Frank Faltinger"

Akademický článek

Intratumoral delivery of TransCon™ TLR7/8 Agonist promotes sustained anti-tumor activity and local immune cell activation while minimizing systemic cytokine induction

Publikováno v: Cancer Cell International, Vol 22, Iss 1, Pp 1-17 (2022)

Abstract Background Intratumoral (IT) delivery of toll-like receptor (TLR) agonists has shown encouraging anti-tumor benefit in preclinical and early clinical studies. However, IT delivery of TLR agonists may lead to rapid effusion from the tumor mic

Externí odkaz: https://doaj.org/article/9c07ff8778c14891ac4c75977cba6fba

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 10, Iss 7 (2022)

Background Recombinant interleukin-2 (IL-2, aldesleukin) is an approved cancer immunotherapy but causes severe toxicities including cytokine storm and vascular leak syndrome (VLS). IL-2 promotes antitumor function of IL-2Rβ/γ+ natural killer (NK) c

Externí odkaz: https://doaj.org/article/c5975468cd0f4febb405f737118e732f

Zobrazit plný text záznamu

TransCon IL-2 β/γ, a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 analog, demonstrates improved pharmacokinetics and profound expansion of cytotoxic immune cells in non-human primates

Publikováno v: Journal of Clinical Oncology. 40:2563-2563

2563 Background: Recombinant interleukin-2 (IL-2, aldesleukin) is an approved cancer immunotherapy but causes severe side effects including cytokine release syndrome (CRS) and vascular leak syndrome (VLS). This is believed to be due to activation of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::35b77b295af74f3d940955738aa84d77
https://doi.org/10.1200/jco.2022.40.16_suppl.2563

Zobrazit plný text záznamu

TransCon CNP, a Sustained-Release C-Type Natriuretic Peptide Prodrug, a Potentially Safe and Efficacious New Therapeutic Modality for the Treatment of Comorbidities Associated with Fibroblast Growth Factor Receptor 3-Related Skeletal Dysplasias

Autor: C.E. Rasmussen, Frank Faltinger, Per Holse Mygind, Ana Bernhard, Mads Kjelgaard-Hansen, Joachim Zettler, Vibeke Miller Breinholt, Ulrich Hersel

Publikováno v: The Journal of pharmacology and experimental therapeutics. 370(3)

TransCon CNP is a C-type natriuretic peptide (CNP-38) conjugated via a cleavable linker to a polyethylene glycol carrier molecule, designed to provide sustained systemic CNP levels upon weekly subcutaneous administration. TransCon CNP is in clinical

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cad3ccad4be0218e78bc707a19580a35
https://pubmed.ncbi.nlm.nih.gov/31235532

Zobrazit plný text záznamu

Design and Preclinical Development of TransCon PTH, an Investigational Sustained-Release PTH Replacement Therapy for Hypoparathyroidism

Autor: Julia Baron, Stefan Heinig, Mathias Krusch, Eric Hoffmann, Steffen Killian, David B Karpf, Kennett Sprogøe, Joachim Zettler, Caroline E Rasmussen, Felix Cleemann, Guillaume Maitro, Vibeke Miller Breinholt, Susanne Pihl, Frank Faltinger, Lars Holten-Andersen, Thomas Wegge

Publikováno v: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 34(11)

Hypoparathyroidism (HP) is a condition of parathyroid hormone (PTH) deficiency leading to abnormal calcium and phosphate metabolism. The mainstay of therapy consists of vitamin D and calcium supplements, as well as adjunct Natpara (PTH(1-84)). Howeve

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e2982cd54c14c0c3fd70191b05fee2a
https://pubmed.ncbi.nlm.nih.gov/31291476

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání